Ocular Therapeutix director buys 60,229 OCUL shares

Ocular Therapeutix director Richard L. Lindstrom, MD, bought shares of the company’s common stock in the open market.

Rhea-AI Filing Summary

Ocular Therapeutix director Richard L. Lindstrom, MD, bought shares of the company’s common stock in the open market. On this transaction date, he purchased 60,229 shares at a weighted average price of $7.66 per share, bringing his directly held stake to 246,933 shares.

Insider Trade Summary

Net Buyer: 60,229 shares

Net Buy 1 txn

Insider LINDSTROM RICHARD L MD

Role Director

Bought 60,229 shs ($461K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	60,229	$7.66	$461K

Holdings After Transaction: Common Stock — 246,933 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.64 to $7.69, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
2. F2. Includes 43,559 shares transferred from the Lindstrom Family No 2 Limited Partnership to the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ocular Therapeutix (OCUL) director Richard Lindstrom report on this Form 4?

Director Richard L. Lindstrom, MD, reported an open-market purchase of Ocular Therapeutix common stock. He acquired 60,229 shares, which increased his directly held ownership position to 246,933 shares following the transaction, according to the Form 4 filing details.

How many Ocular Therapeutix (OCUL) shares did the director buy and at what price?

He bought 60,229 shares of Ocular Therapeutix common stock. The filing states a weighted average purchase price of $7.66 per share, with individual trade prices ranging between $7.64 and $7.69 across multiple transactions executed that day.

What is Richard Lindstrom’s total Ocular Therapeutix (OCUL) ownership after this transaction?

After this reported transaction, Richard L. Lindstrom, MD, directly owns 246,933 shares of Ocular Therapeutix common stock. This total reflects the newly purchased 60,229 shares as well as shares that were already held in his direct ownership before the acquisition.

Was the Ocular Therapeutix (OCUL) insider trade an open-market purchase or another type?

The transaction was an open-market purchase of common stock. The Form 4 codes it as a “P” transaction, described as a purchase in an open market or private transaction, and classifies it as a non-derivative acquisition of Ocular Therapeutix shares.

What pricing details are disclosed for the Ocular Therapeutix (OCUL) insider share purchase?

The filing reports a weighted average price of $7.66 per share. Footnotes explain the director’s shares were bought in multiple trades at prices ranging from $7.64 to $7.69, and that full trade-by-trade price information is available upon request.

Did the Ocular Therapeutix (OCUL) Form 4 mention any transfers related to the director’s holdings?

Yes. A footnote explains that the reported holdings include 43,559 shares transferred from the Lindstrom Family No 2 Limited Partnership to the reporting person. These transferred shares are part of the total direct ownership now shown in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/24/2026 - 06:13 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINDSTROM RICHARD L MD

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		P		60,229	A	$7.66(1)	246,933(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.64 to $7.69, inclusive. The reporting person undertakes to provide to Ocular Therapeutix, Inc., any security holder of Ocular Therapeutix, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

2. Includes 43,559 shares transferred from the Lindstrom Family No 2 Limited Partnership to the reporting person.

	/s/ Todd Anderman, Attorney-in-Fact for Richard L. Lindstrom, M.D.	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.